Table 4 PCR-corrected treatment outcomes
Treatment Outcome | Artemether–lumefantrine | Artesunate-amodiaquine | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Doba (n = 31) | Kelo (n = 48) | Kayom (n = 35) | Doba (n = 33) | Kelo (n = 33) | Kayom (n = 35) | |||||||
n (%) | CI 95% | n (%) | 95% CI | n (%) | 95% CI | n (%) | CI 95% | n (%) | 95% CI | n (%) | 95% CI | |
Per-protocol | ||||||||||||
ETF | 0 (0) | 0.0–12.3 | 0 (0) | 0.0–7.9 | 0 (0) | 0.0–10.3 | 0 (0) | 0.0–11.9 | 0 (0) | 0.0–11.2 | 0 (0) | 0.0–10.6 |
LCF | 0 (0) | 0.0–12.3 | 0 (0) | 0.0–7.9 | 0 (0) | 0.0–10.3 | 0 (0) | 0.0–11.9 | 0 (0) | 0.0–11.2 | 0 (0) | 0.0–10.6 |
LPF | 0 (0) | 0.0–12.3 | 1 (2.2) | 0.1–11.8 | 0 (0) | 0.0–10.3 | 0 (0) | 0.0–11.9 | 0 (0) | 0.0–11.2 | 0 (0) | 0.0–10.6 |
ACPR | 28 (100) | 87.7–100 | 44 (97.8) | 88.2–100 | 34 (100) | 89.7–100 | 29 (100) | 88.1–100 | 31 (100) | 88.8–100 | 33 (100) | 89.4–100 |
Total per-protocol | 28 | 45 | 34 | 29 | 31 | 33 | ||||||
Withdrawn/lost: | 3 (9.7) | 3 (6.3) | 1 (2.9) | 4 (12.1) | 2 (6.1) | 2 (5.7) | ||||||
Re-infection | – | 3 (6.3) | – | – | – | – | ||||||
Kaplan–Meier | ||||||||||||
Cure rate | 100 | NA | 97.9 | 86.1–99.7 | 100 | NA | 100 | NA | 100 | NA | 100 | NA |